Insider Transactions in Q1 2025 at Ptc Therapeutics, Inc. (PTCT)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
6,762
-2.19%
|
$378,672
$56.96 P/Share
|
|
Mar 14
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,458
-5.32%
|
$245,190
$55.19 P/Share
|
|
Mar 13
2025
|
Stephanie Okey |
SELL
Open market or private sale
|
Direct |
5,000
-36.06%
|
$270,000
$54.0 P/Share
|
|
Mar 12
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
15,521
-6.73%
|
$822,613
$53.27 P/Share
|
|
Mar 12
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,521
+6.14%
|
$512,193
$33.02 P/Share
|
|
Mar 11
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
7,381
-3.4%
|
$391,193
$53.01 P/Share
|
|
Mar 11
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,381
+3.26%
|
$243,573
$33.02 P/Share
|
|
Mar 10
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
68,039
-12.57%
|
$3,538,028
$52.89 P/Share
|
|
Mar 10
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
68,039
+13.74%
|
$2,041,170
$30.58 P/Share
|
|
Mar 04
2025
|
Allan Steven Jacobson |
SELL
Open market or private sale
|
Direct |
1,230
-6.04%
|
$62,730
$51.52 P/Share
|
|
Feb 20
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
34
-0.57%
|
$1,700
$50.12 P/Share
|
|
Feb 20
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,578
-1.55%
|
$78,900
$50.12 P/Share
|
|
Feb 20
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,614
-1.53%
|
$80,700
$50.12 P/Share
|
|
Feb 20
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
962
-1.24%
|
$48,100
$50.12 P/Share
|
|
Feb 20
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-1.39%
|
$194,750
$50.12 P/Share
|
|
Feb 20
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,567
-1.83%
|
$78,350
$50.12 P/Share
|
|
Feb 20
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,167
-1.54%
|
$58,350
$50.12 P/Share
|
|
Feb 20
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
878
-1.38%
|
$43,900
$50.12 P/Share
|
|
Feb 19
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
34
-0.57%
|
$1,700
$50.1 P/Share
|
|
Feb 19
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,300
-1.26%
|
$65,000
$50.1 P/Share
|
|
Feb 19
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,333
-1.25%
|
$66,650
$50.1 P/Share
|
|
Feb 19
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
795
-1.01%
|
$39,750
$50.1 P/Share
|
|
Feb 19
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,897
-1.37%
|
$194,850
$50.1 P/Share
|
|
Feb 19
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,378
-1.59%
|
$68,900
$50.1 P/Share
|
|
Feb 19
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,168
-1.52%
|
$58,400
$50.1 P/Share
|
|
Feb 19
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
879
-1.37%
|
$43,950
$50.1 P/Share
|
|
Jan 08
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
107
-1.76%
|
$4,708
$44.5 P/Share
|
|
Jan 08
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,552
-1.48%
|
$68,288
$44.5 P/Share
|
|
Jan 08
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,998
-1.84%
|
$87,912
$44.5 P/Share
|
|
Jan 08
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,198
-1.5%
|
$52,712
$44.5 P/Share
|
|
Jan 08
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,402
-0.84%
|
$105,688
$44.5 P/Share
|
|
Jan 08
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
2,136
-2.4%
|
$93,984
$44.5 P/Share
|
|
Jan 08
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,662
-2.52%
|
$73,128
$44.5 P/Share
|
|
Jan 07
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
55
-0.9%
|
$2,475
$45.34 P/Share
|
|
Jan 07
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,265
-1.19%
|
$56,925
$45.34 P/Share
|
|
Jan 07
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,543
-1.4%
|
$69,435
$45.34 P/Share
|
|
Jan 07
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
810
-1.0%
|
$36,450
$45.34 P/Share
|
|
Jan 07
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
2,142
-0.74%
|
$96,390
$45.34 P/Share
|
|
Jan 07
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,599
-1.77%
|
$71,955
$45.34 P/Share
|
|
Jan 07
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,291
-1.92%
|
$58,095
$45.34 P/Share
|
|
Jan 03
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+19.53%
|
-
|
|
Jan 03
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+22.67%
|
-
|
|
Jan 03
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+19.55%
|
-
|
|
Jan 03
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+19.87%
|
-
|
|
Jan 03
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
715
+10.43%
|
-
|
|
Jan 03
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+15.19%
|
-
|
|
Jan 03
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+14.02%
|
-
|
|
Jan 03
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+17.23%
|
-
|
|
Jan 03
2025
|
Michael Schmertzler |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+5.74%
|
-
|
|
Jan 03
2025
|
Allan Steven Jacobson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+16.43%
|
-
|